Encapsulated cell therapy - Bavarian Nordic

Drug Profile

Encapsulated cell therapy - Bavarian Nordic

Alternative Names: CapCell; CapCell/chemotherapy

Latest Information Update: 19 Mar 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bavarian Nordic
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 19 Mar 2004 CapCell™ cell encapsulation technology is available for licensing worldwide (http://www.bavarian-nordic.com)
  • 23 Sep 2002 Suspended - Phase-II for Pancreatic cancer in Germany (IV-infusion)
  • 23 Sep 2002 Suspended - Phase-II for Pancreatic cancer in Switzerland (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top